Angiogenesis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Angiogenesis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
TransMolecular
TransMolecular Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting
June 19th, 2009
TransMolecular, Inc. announced new data highlighting the anti-angiogenic and tumor-targeting properties of TM601 in a poster presentation and in a published abstract at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). In a clinical study of patients with recurrent glioblastoma, the first cohort of patients analyzed showed correlative reductions in vascular perfusion and prolongation of progression-free survival. A separate clinical study, utilizing radiolabeled TM601, demonstrated highly specific tumor uptake of intravenously delivered 131I-TM601 in several different primary and metastatic tumor types, including glioma, metastatic melanoma, pancreatic cancer,...
Source: Angiogenesis Weekly (2009-06-19)
|
